BioCentury | Apr 15, 2013
Clinical News

Spirogen preclinical data

In mouse xenograft models of breast cancer and hematological tumors, a series of trastuzumab antibody-drug conjugates (ADCs) containing cytotoxic pyrrolobenzodiazepine (PBD) dimer drug linkers produced durable complete regressions and led to tumor-free survival. The products...
BioCentury | Jul 19, 2012
Targets & Mechanisms

OutFOXing tumors

...chemistry aspect of the project, and his team was a recipient of the 2012 NYCIF BioAccelerate...
BioCentury | Sep 4, 2006
Company News

Gardent Pharmaceuticals Inc., Symbollon, Switch Pharma deal

...pain and tenderness associated with fibrocystic breast disease (see BioCentury, April 18, 2005). GRDP, formerly Bioaccelerate...
BioCentury | Aug 21, 2006
Clinical News

RP101: Phase II start

...of RP101 plus gemcitabine to gemcitabine plus placebo. Avantogen Oncology Inc. (AVTO), Los Angeles, Calif. Bioaccelerate...
BioCentury | Aug 21, 2006
Clinical News

RP101: Interim Phase I data

...respectively. The estimated median survival was 9.3 months. Avantogen Oncology Inc. (AVTO), Los Angeles, Calif. Bioaccelerate...
BioCentury | Aug 7, 2006
Company News

ArQule management update

...Business: Cancer Hired: Nigel Rulewski as CMO, formerly SVP of Bioaccelerate Holdings Inc. , now Gardant Pharmaceuticals Inc. WIR...
BioCentury | Jun 12, 2006
Clinical News

RP101: Interim Phase II data

...at the American Society of Clinical Oncology meeting in Atlanta. Avantogen Ltd. (ASX:ACU), Sydney, Australia Bioaccelerate...
BioCentury | Apr 3, 2006
Company News

CuraGen management update

...Conn. Business: Cancer, Inflammation, Endocrine Hired: Frank Armstrong as president and CEO, formerly CEO of Bioaccelerate...
BioCentury | Mar 31, 2006
Company News

CuraGen names Armstrong CEO

...hired Frank Armstrong as president and CEO. Armstrong, a CRGN director, previously was CEO of Bioaccelerate...
BioCentury | Sep 26, 2005
Clinical News

RP101: Additional Phase I/II data

...at the Tumor Progression and Therapeutic Resistance meeting in Boston. Avantogen Ltd. (ASX:ACU), Sydney, Australia Bioaccelerate...
Items per page:
1 - 10 of 16
BioCentury | Apr 15, 2013
Clinical News

Spirogen preclinical data

In mouse xenograft models of breast cancer and hematological tumors, a series of trastuzumab antibody-drug conjugates (ADCs) containing cytotoxic pyrrolobenzodiazepine (PBD) dimer drug linkers produced durable complete regressions and led to tumor-free survival. The products...
BioCentury | Jul 19, 2012
Targets & Mechanisms

OutFOXing tumors

...chemistry aspect of the project, and his team was a recipient of the 2012 NYCIF BioAccelerate...
BioCentury | Sep 4, 2006
Company News

Gardent Pharmaceuticals Inc., Symbollon, Switch Pharma deal

...pain and tenderness associated with fibrocystic breast disease (see BioCentury, April 18, 2005). GRDP, formerly Bioaccelerate...
BioCentury | Aug 21, 2006
Clinical News

RP101: Phase II start

...of RP101 plus gemcitabine to gemcitabine plus placebo. Avantogen Oncology Inc. (AVTO), Los Angeles, Calif. Bioaccelerate...
BioCentury | Aug 21, 2006
Clinical News

RP101: Interim Phase I data

...respectively. The estimated median survival was 9.3 months. Avantogen Oncology Inc. (AVTO), Los Angeles, Calif. Bioaccelerate...
BioCentury | Aug 7, 2006
Company News

ArQule management update

...Business: Cancer Hired: Nigel Rulewski as CMO, formerly SVP of Bioaccelerate Holdings Inc. , now Gardant Pharmaceuticals Inc. WIR...
BioCentury | Jun 12, 2006
Clinical News

RP101: Interim Phase II data

...at the American Society of Clinical Oncology meeting in Atlanta. Avantogen Ltd. (ASX:ACU), Sydney, Australia Bioaccelerate...
BioCentury | Apr 3, 2006
Company News

CuraGen management update

...Conn. Business: Cancer, Inflammation, Endocrine Hired: Frank Armstrong as president and CEO, formerly CEO of Bioaccelerate...
BioCentury | Mar 31, 2006
Company News

CuraGen names Armstrong CEO

...hired Frank Armstrong as president and CEO. Armstrong, a CRGN director, previously was CEO of Bioaccelerate...
BioCentury | Sep 26, 2005
Clinical News

RP101: Additional Phase I/II data

...at the Tumor Progression and Therapeutic Resistance meeting in Boston. Avantogen Ltd. (ASX:ACU), Sydney, Australia Bioaccelerate...
Items per page:
1 - 10 of 16